Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor. It is applicable in research on metastatic cancer and squamous cell skin cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $163 | In Stock | |
5 mg | $497 | In Stock | |
10 mg | $797 | In Stock |
Description | Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody that inhibits the PD-1/PD-L1 pathway, serving as a checkpoint inhibitor. It is applicable in research on metastatic cancer and squamous cell skin cancer. |
In vivo | In a mouse model with MC38.Ova tumors, Cemiplimab (i.p., 10 mg/kg, five injections within 2 weeks) increased the proportion of effector T cells in tumors and dLNs, resulting in reduced tumor growth when combined with immunotherapy using REGN3767[2]. |
Alias | SAR-439684, REGN-2810 |
Molecular Weight | 143.81 kDa |
Cas No. | 1801342-60-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.